The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
The role of mechanoinflammation in the pathogenesis of psoriatic disease and the presence of entheseal lesions as predictors of the onset of clinical joint disease gain support in a new study.
A significant association between indoor tanning frequency and a diagnosis of psoriasis was noted; physicians should caution their patients with psoriasis against the use of non-medical indoor tanning as a therapy.
The reported UTI IR with IXE is low and that those patients who do experience UTI were most likely predisposed based on known risk factors.
In the absence of COVID-19-specific data, published research may serve to guide treatment with biologic agents in patients with psoriasis.
At nearly a fifth of all patient visits for psoriasis, systemic agents are prescribed; biologic agents were the most frequently used for treatment.
A novel trial examining dose reduction strategies for biologic agents for the treatment of psoriasis found that successful dose tapering was possible in more than half of patients, which can have an effect on healthcare expenditures.
Disease activity in psoriatic arthritis may be positively correlated with body adiposity, saturated fat consumption, and serum cholesterol levels.
Risankizumab is superior to adalimumab for improving psoriasis, based on assessments using the PASI and sPGA score.
A Western diet can, in as little as 4 weeks, result in clinically and molecularly significant proinflammatory changes in the skin, underscoring the relationship between dietary components and skin disease.